Regenerex Pharma (RGPX) Equity Ratio (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Equity Ratio data on file, last reported at 7.61 in Q3 2025.

• Equity Ratio for Q3 2025 came in at 7.61, down 1.2% year-over-year; the trailing twelve-month figure through Sep 2025 was 7.61 (down 1.2% YoY), and the FY2025 annual result was 3.29, up 37.9% from the prior year.
• Equity Ratio declined to 7.61 in Q3 2025 per RGPX's latest filing, from 5.96 in the prior quarter.
• Over five years, Equity Ratio peaked at 1.04 in Q2 2023 and troughed at 171.73 in Q1 2023.
• A 5-year average of 48.72 and a median of 7.81 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2021 and 2023: Equity Ratio tumbled 4194.78% in 2021, then surged 98.91% in 2023.
• A 5-year view of Equity Ratio shows it stood at 82.1 in 2021, then plunged by 32.08% to 108.44 in 2022, then surged by 95.81% to 4.55 in 2023, then tumbled by 71.76% to 7.81 in 2024, then gained by 2.64% to 7.61 in 2025.
• Business Quant data shows RGPX's Equity Ratio at 7.61 in Q3 2025, 5.96 in Q2 2025, and 3.29 in Q1 2025.